The FDA has not approved a stem-cell therapy specifically for anemia as a licensed product, despite the large number of trials. Haematopoietic stem-cell transplantation (from bone marrow or cord blood) remains the only FDA-cleared cellular therapy for severe aplastic anaemia and certain myelodysplastic syndromes, but this differs from MSC-based approaches. Investigational MSC therapies for anemia are registered with the NIH but remain unapproved. The EMA has not granted a marketed anemia-specific MSC product. Patients should distinguish approved haematologic transplantation from investigational MSC protocols.
Anemia encompasses diverse disorders characterised by insufficient red-blood-cell mass or haemoglobin production, ranging from iron deficiency and chronic disease anaemia to haemolytic syndromes and bone-marrow disorders. Stem-cell research investigates whether placental mesenchymal stem cells and fetal stem cells can stimulate erythropoiesis, enhance iron metabolism, reduce chronic inflammation driving anaemia, and regenerate damaged haematopoietic niches. With 531 registered trials — by far the largest evidence base among studied conditions — and 83 currently recruiting, the scope encompasses both direct support of erythroid progenitors and paracrine reduction of inflammatory barriers to red-cell production. The diversity of anaemia aetiologies means that stem-cell approaches must be matched to underlying pathophysiology: supportive in chronic renal disease, immunomodulatory in autoimmune haemolytic anaemia, regenerative in aplastic anaemia.
Am I a candidate? → · Anemia: full overview → · Anemia cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment